Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Alerts
  • Advertising/recruitment
  • Subscribe
  • Contact
  • Current Issue
  • Past Issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • 100th Anniversary of Insulin's Discovery (Jan 2021)
    • Hypoxia-inducible factors in disease pathophysiology and therapeutics (Oct 2020)
    • Latency in Infectious Disease (Jul 2020)
    • Immunotherapy in Hematological Cancers (Apr 2020)
    • Big Data's Future in Medicine (Feb 2020)
    • Mechanisms Underlying the Metabolic Syndrome (Oct 2019)
    • Reparative Immunology (Jul 2019)
    • View all review series ...
  • Viewpoint
  • Collections
    • Recently published
    • In-Press Preview
    • Commentaries
    • Concise Communication
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • Recently published
  • In-Press Preview
  • Commentaries
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Alerts
  • Advertising/recruitment
  • Subscribe
  • Contact
SUMO-defective c-Maf preferentially transactivates Il21 to exacerbate autoimmune diabetes
Chao-Yuan Hsu, … , Deh-Ming Chang, Huey-Kang Sytwu
Chao-Yuan Hsu, … , Deh-Ming Chang, Huey-Kang Sytwu
Published July 30, 2018
Citation Information: J Clin Invest. 2018;128(9):3779-3793. https://doi.org/10.1172/JCI98786.
View: Text | PDF
Research Article Autoimmunity Immunology

SUMO-defective c-Maf preferentially transactivates Il21 to exacerbate autoimmune diabetes

  • Text
  • PDF
Abstract

SUMOylation is involved in the development of several inflammatory diseases, but the physiological significance of SUMO-modulated c-Maf in autoimmune diabetes is not completely understood. Here, we report that an age-dependent attenuation of c-Maf SUMOylation in CD4+ T cells is positively correlated with the IL-21–mediated diabetogenesis in NOD mice. Using 2 strains of T cell–specific transgenic NOD mice overexpressing wild-type c-Maf (Tg-WTc) or SUMOylation site–mutated c-Maf (Tg-KRc), we demonstrated that Tg-KRc mice developed diabetes more rapidly than Tg-WTc mice in a CD4+ T cell–autonomous manner. Moreover, SUMO-defective c-Maf preferentially transactivated Il21 to promote the development of CD4+ T cells with an extrafollicular helper T cell phenotype and expand the numbers of granzyme B–producing effector/memory CD8+ T cells. Furthermore, SUMO-defective c-Maf selectively inhibited recruitment of Daxx/HDAC2 to the Il21 promoter and enhanced histone acetylation mediated by CREB-binding protein (CBP) and p300. Using pharmacological interference with CBP/p300, we illustrated that CBP30 treatment ameliorated c-Maf–mediated/IL-21–based diabetogenesis. Taken together, our results show that the SUMOylation status of c-Maf has a stronger regulatory effect on IL-21 than the level of c-Maf expression, through an epigenetic mechanism. These findings provide new insights into how SUMOylation modulates the pathogenesis of autoimmune diabetes in a T cell–restricted manner and on the basis of a single transcription factor.

Authors

Chao-Yuan Hsu, Li-Tzu Yeh, Shin-Huei Fu, Ming-Wei Chien, Yu-Wen Liu, Shi-Chuen Miaw, Deh-Ming Chang, Huey-Kang Sytwu

×

Figure 2

Accelerated kinetics of autoimmune diabetes in SUMO-defective c-Maf–transgenic NOD mice.

Options: View larger image (or click on image) Download as PowerPoint
Accelerated kinetics of autoimmune diabetes in SUMO-defective c-Maf–tran...
(A) Schematic diagram of distal Lck promoter–driven wild-type c-Maf or K33R c-Maf transgenes. (B) PCR detection of transgenic c-Maf in genomic DNA extracted from control, Tg-WTc, and Tg-KRc mice. Il23 p19 was used as an internal control. (C) Western blot analysis of c-Maf in control, Tg-WTc, and Tg-KRc CD4+ T cells. (D and E) Immunoprecipitation analysis of c-Maf SUMOylation in control, Tg-WTc, and Tg-KRc CD4+ T cells cultured with anti-CD3 and anti-CD28 for 36 hours. (F) Diabetes incidence in Tg-WTc NOD mice and their littermate controls. (G) Diabetes incidence in Tg-KRc NOD mice and their littermate controls. (H) Diabetes incidence in NOD-SCID recipients of splenocytes from 12- to 14-week-old control, Tg-WTc, or Tg-KRc NOD mice. (I and J) CD25–CD4+ plus CD8+ T cells from 12- to 14-week-old indicated NOD mice were transferred into NOD.Rag1–/– mice; all groups were treated simultaneously in 2 independent experiments. The control CD4/control CD8 (white circles) group is presented in both I and J. Diabetic incidences among groups that received control CD8+ T cells plus different CD4+ T cells (I) and diabetic incidences in among groups that received control CD4+ T cells plus different CD8+ T cells (J) were compared with each other by a log-rank test. See complete unedited blots in the supplemental material. For E, data represent the mean ± SEM; n = 3 mice (B and C) or n = 5 mice (D and E) per group; 3 independent experiments (B–E) or 2 independent experiments (H). *P < 0.05; **P < 0.01; 1-way ANOVA with Tukey’s post-test (E) or log-rank test (F–J).
Follow JCI:
Copyright © 2021 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts